GeneDx (NASDAQ:WGS) Hits New 52-Week High at $22.75

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $22.75 and last traded at $22.61, with a volume of 174152 shares traded. The stock had previously closed at $20.75.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on WGS. The Goldman Sachs Group increased their target price on shares of GeneDx to $11.00 and gave the stock a "neutral" rating in a report on Monday, April 15th. TD Cowen upped their price objective on GeneDx from $14.00 to $24.00 and gave the stock a "buy" rating in a research note on Tuesday, April 30th. Finally, BTIG Research upped their price target on shares of GeneDx from $15.00 to $19.00 and gave the stock a "buy" rating in a research note on Tuesday, April 30th.

GeneDx Trading Up 12.7 %

The company has a fifty day simple moving average of $11.54 and a two-hundred day simple moving average of $6.13. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.22 and a quick ratio of 2.99. The company has a market capitalization of $610.69 million, a P/E ratio of -4.51 and a beta of 2.17.

GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings results on Tuesday, February 20th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.60) by $0.01. GeneDx had a negative net margin of 60.86% and a negative return on equity of 36.23%. The company had revenue of $57.42 million during the quarter, compared to analysts' expectations of $57.00 million. On average, analysts forecast that GeneDx Holdings Corp. will post -2.02 earnings per share for the current fiscal year.

Insider Transactions at GeneDx

In other GeneDx news, CFO Kevin Feeley sold 3,253 shares of the company's stock in a transaction on Monday, March 18th. The stock was sold at an average price of $10.59, for a total value of $34,449.27. Following the sale, the chief financial officer now directly owns 28,927 shares in the company, valued at $306,336.93. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CFO Kevin Feeley sold 3,253 shares of the stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $10.59, for a total value of $34,449.27. Following the transaction, the chief financial officer now directly owns 28,927 shares in the company, valued at $306,336.93. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Katherine Stueland sold 6,325 shares of GeneDx stock in a transaction on Monday, April 29th. The stock was sold at an average price of $11.04, for a total transaction of $69,828.00. Following the sale, the chief executive officer now directly owns 75,869 shares of the company's stock, valued at approximately $837,593.76. The disclosure for this sale can be found here. In the last quarter, insiders have sold 21,249 shares of company stock valued at $228,370. 28.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Oracle Investment Management Inc. increased its stake in GeneDx by 14.9% in the 3rd quarter. Oracle Investment Management Inc. now owns 994,580 shares of the company's stock valued at $3,620,000 after buying an additional 128,731 shares during the last quarter. Decheng Capital LLC bought a new position in GeneDx in the fourth quarter valued at approximately $285,000. Pathstone Family Office LLC raised its stake in shares of GeneDx by 262.2% during the 3rd quarter. Pathstone Family Office LLC now owns 54,327 shares of the company's stock worth $198,000 after purchasing an additional 39,327 shares in the last quarter. HighTower Advisors LLC grew its stake in shares of GeneDx by 14.1% in the third quarter. HighTower Advisors LLC now owns 237,948 shares of the company's stock valued at $865,000 after buying an additional 29,361 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in GeneDx by 4.2% during the first quarter. Vanguard Group Inc. now owns 707,612 shares of the company's stock worth $6,460,000 after buying an additional 28,678 shares during the last quarter. Institutional investors and hedge funds own 61.72% of the company's stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.